Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • GSK drug Zejula helps...

    GSK drug Zejula helps ovarian cancer patients live longer in late-stage study

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-07-16T09:26:14+05:30  |  Updated On 16 Aug 2021 10:46 AM IST

    GSK bought the drug when it acquired U.S. cancer specialist Tesaro for $5.1 billion in December and Zejula is already approved for certain ovarian cancer patients.


    New Delhi: GlaxoSmithKline Plc's cancer treatment Zejula met the main goal of helping patients with ovarian cancer live longer without their disease worsening in a late-stage study, the company said on Monday.


    The company bought the drug when it acquired U.S. cancer specialist Tesaro for $5.1 billion in December and Zejula is already approved for certain ovarian cancer patients.


    The study, called PRIMA, tested the treatment as maintenance therapy in women who have undergone platinum-based chemotherapy and met the main goal for women regardless of their biomarker status, GSK said.


    Read Also: GSK to appoint Novartis, Astrazeneca ex-executive Jonathan Symonds as new Chairman: Bloomberg


    A biomarker status helps identify if patients have a particular genetic mutation which determines how a drug can be used and how its effectiveness is tested and measured.


    For GSK, the success of Zejula would help it access a wider population group and give it an edge over rival PARP inhibitors such as AstraZeneca and Merck & Co's Lynparza and Clovis Oncology's Rubraca.


    "Zejula's potential to expand PARP use beyond BRCAm (BRCA mutation) patients, was a key justification for its Tesaro acquisition and this required a positive outcome for Zejula in the PRIMA study," Jefferies analysts said.


    Mutations in the BRCA genes impair the ability to repair DNA damage, which can drive cancer growth.


    PARP inhibitors are a class of drugs which work by blocking enzymes involved in repairing damaged DNA, thereby helping to kill cancer cells, and are a growing focus for drug research, with potential for use in breast, lung and prostate cancers.


    Jefferies analysts estimate potential peak sales of $550 million for Zejula in first-line ovarian cancer maintenance.


    Read Also: GSK to fund doctoral programs at Government established Regional Centre for Biotechnology


    About 300,000 women globally are diagnosed with ovarian cancer each year, and only about 15% of patients are currently eligible to receive PARP inhibitors as their initial therapy, GSK said in a statement.


    Ovarian cancer is the fifth most frequent cause of cancer death among women, it added.


    Currently, AstraZeneca's Lynparza, which sells nearly three times more than Zejula, is approved as a first-line maintenance treatment for advanced BRCA-mutated ovarian cancer.


    GSK has been focusing on bolstering its cancer drug pipeline, and earlier this year agreed to pay up to 3.7 billion euros ($4.17 billion) to Germany's Merck KGaA for the rights to next-generation immunotherapy.

    AstraZenecacancer last stageGlaxoSmithKlineGSKgsk drugimmunotherapylast stage trialovarian cancerovarian cancer ZejulaPARP inhibitorsPRIMATesaroZejula
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok